Cephalon Inc. and Tanabe Seiyaku Announce License Agreement for ACTIQ in Japan.
Cephalon Inc. and Tanabe Seiyaku Co. Ltd. announced a license agreement for Tanabe to commercialize ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II] in Japan. As Cephalon's exclusive licensee, Tanabe will develop, register and market ACTIQ and any future formulations or improvements of the product in Japan for the management of breakthrough pain in cancer patients. In addition, Tanabe will have the opportunity to develop and commercialize other breakthrough pain products from Cephalon in Japan.
